Stock SHUKRAPHAR6 SHUKRA PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shukra Pharmaceuticals Limited

Equities

SHUKRAPHAR6

INE551C01028

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 11:00:56 01/07/2024 BST 		5-day change 1st Jan Change
109.2 INR -1.97% Intraday chart for Shukra Pharmaceuticals Limited -9.53% +252.97%
05-29 Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023- 24 CI
05-29 Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 96.6 57.23 73.2 69.67 94.57 514.3
Enterprise Value (EV) 1 133.4 118.8 152.4 162.3 127.5 525.4
P/E ratio 18.4 x 12.4 x 206 x 37 x 12.6 x 1.79 x
Yield 0.81% 1.37% - - 0.83% 1.07%
Capitalization / Revenue 1.81 x 1.01 x 0.62 x 0.62 x 0.46 x 0.86 x
EV / Revenue 2.5 x 2.1 x 1.29 x 1.45 x 0.62 x 0.88 x
EV / EBITDA 8.26 x 7.2 x 9.9 x 11.2 x 4.34 x 8.09 x
EV / FCF -3.06 x -4.7 x -8.16 x -10.9 x 2.2 x -12.1 x
FCF Yield -32.6% -21.3% -12.3% -9.16% 45.5% -8.28%
Price to Book 0.64 x 0.37 x 0.47 x 0.45 x 0.58 x 2.03 x
Nbr of stocks (in thousands) 6,263 6,263 6,263 6,263 6,263 43,839
Reference price 2 15.42 9.138 11.69 11.12 15.10 11.73
Announcement Date 21/10/18 07/01/20 26/01/21 23/09/21 05/09/22 25/08/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 53.44 56.6 118.5 112 205 594.9
EBITDA 1 16.15 16.49 15.4 14.44 29.35 64.96
EBIT 1 8.784 6.867 0.6216 -0.2979 12.73 46.59
Operating Margin 16.44% 12.13% 0.52% -0.27% 6.21% 7.83%
Earnings before Tax (EBT) 1 9.462 7.244 1.708 0.9782 10.18 44.42
Net income 1 5.257 4.62 0.356 1.881 7.507 44.06
Net margin 9.84% 8.16% 0.3% 1.68% 3.66% 7.41%
EPS 2 0.8394 0.7377 0.0568 0.3004 1.198 6.553
Free Cash Flow 1 -43.53 -25.29 -18.68 -14.88 57.97 -43.52
FCF margin -81.45% -44.69% -15.77% -13.29% 28.29% -7.32%
FCF Conversion (EBITDA) - - - - 197.54% -
FCF Conversion (Net income) - - - - 772.23% -
Dividend per Share 2 0.1250 0.1250 - - 0.1250 0.1250
Announcement Date 21/10/18 07/01/20 26/01/21 23/09/21 05/09/22 25/08/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 36.8 61.6 79.3 92.7 32.9 11.1
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.277 x 3.733 x 5.145 x 6.417 x 1.121 x 0.1706 x
Free Cash Flow 1 -43.5 -25.3 -18.7 -14.9 58 -43.5
ROE (net income / shareholders' equity) 3.55% 3.04% 0.23% 1.21% 4.7% 21.2%
ROA (Net income/ Total Assets) 2.55% 1.64% 0.13% -0.05% 2.25% 5.29%
Assets 1 206.1 282.5 283.9 -3,452 333.7 833
Book Value Per Share 2 24.00 24.60 24.60 24.90 26.10 5.770
Cash Flow per Share 2 0.1000 0.4000 0.2000 0.8100 0.1400 0.9100
Capex 1 47.5 24.5 32.2 18.1 15.5 44.9
Capex / Sales 88.84% 43.28% 27.2% 16.13% 7.56% 7.55%
Announcement Date 21/10/18 07/01/20 26/01/21 23/09/21 05/09/22 25/08/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
SHUKRA PHARMACEUTICALS LIMITED Stock Shukra Pharmaceuticals Limited
+252.97% 58.52M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.70% 43.77B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+30.16% 22.83B
CIPLA LIMITED Stock Cipla Limited
+18.68% 14.34B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+54.86% 12.96B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.72% 6.41B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.65% 5.69B
GEDEON RICHTER Stock Gedeon Richter
+9.49% 4.75B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SHUKRAPHAR6 Stock
  4. Financials Shukra Pharmaceuticals Limited